Exploring the Lasting Impact of the Altius® System on Pain Relief
Revolutionizing Pain Management for Amputees
In a groundbreaking development for the medical field, Neuros Medical, Inc. has showcased the impressive outcomes of its Altius® Direct Electrical Nerve Stimulation System. This innovative approach offers significant and durable pain relief, particularly for those enduring the challenges of chronic post-amputation pain. Recent findings from the pivotal QUEST study reflect a remarkable decrease in pain levels, reduced reliance on opioids, and enhanced quality of life among amputee patients.
Promising Results from the QUEST Study
The QUEST study stands as a testament to the effectiveness of the Altius® System. This extensive study engaged 180 patients with unilateral lower limb amputations, operating across 35 sites. As one of the largest randomized studies of its kind, it unearthed crucial data regarding chronic pain management following limb loss.
Key Findings and Patient Benefits
The results from the 12-month evaluation were nothing short of impressive. Participants using the Altius® System reported a drop in their pain intensity by 30% as soon as 30 minutes post-treatment, escalating to a 50% reduction after two hours. This level of improvement indicates that the treatment is both clinically effective and meaningful for the patients involved.
Reduction in Opioid Use
A staggering 81% of the patients who had been taking opioids noticed a significant decrease or complete cessation of opioid use after beginning therapy with the Altius® System. This reduction is crucial as it promotes better health outcomes while decreasing the risk of addiction and other opioid-related complications.
Enhanced Quality of Life
Moreover, the study revealed a 45% improvement in the overall quality of life reported by participants. Living with chronic pain is not just physically exhausting; it also takes a toll on mental health and well-being. Therefore, findings like this offer hope for a brighter future for those affected.
The Importance of On-Demand Pain Management
According to Dr. John Eidt, a prominent figure in vascular surgery, the Altius® System provides a solution for chronic post-amputation pain that is patient-controlled and on-demand. This means individuals can manage their pain actively without turning to traditional opioids, paving the way for a new standard in pain relief.
Commercialization and Future Steps
Neuros Medical is set to move forward with the commercialization of the Altius® System, aiming to make this groundbreaking technology accessible to healthcare providers and patients in need. With upcoming steps scheduled, the organization is dedicated to ensuring that individuals who struggle with chronic pain have access to effective treatment options.
About the Altius® System
The Altius® Direct Electrical Nerve Stimulation System operates by blocking pain signals that travel from peripheral nerves to the brain. The system consists of a nerve cuff electrode and an implantable pulse generator, allowing patients the freedom to manage their pain by initiating treatment when necessary.
Neuros Medical’s Mission and Vision
Neuros Medical is driven by an unwavering commitment to improve the lives of individuals grappling with post-amputation pain. With a deep understanding of the physical and emotional struggles these patients face, the company strives to develop innovative technologies that can effectively address their needs and enhance their quality of life.
Frequently Asked Questions
What is the Altius® System?
The Altius® System is a Direct Electrical Nerve Stimulation technology developed by Neuros Medical to help alleviate chronic post-amputation pain by inhibiting pain signals.
How effective is the Altius® System according to recent studies?
Recent studies indicate that patients using the Altius® System experienced significant pain reduction and improved quality of life, with many reducing or eliminating opioid use.
Who can benefit from the Altius® System?
Individuals with chronic post-amputation pain, particularly lower limb amputees, can benefit greatly from the Altius® technology.
Is the Altius® System FDA approved?
Yes, the Altius® System is approved by the FDA for use in pain management for amputees.
How can patients access the Altius® System?
Patients can access the Altius® System through healthcare providers once commercialization starts later this year.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Discover the Pre-registration for Bybit's Physical Card
- Top Semiconductor Stocks to Watch Amid AI Demand Growth
- The Expanding Nitrile Gloves Market and Its Growth Potential
- Welshare Health's New AI App Revolutionizes Patient Research
- Calian Group Partners with Microsoft for Cloud Cybersecurity Solutions
- Covalon Technologies to Showcase Innovations in Vascular Access Care
- Flow Beverage Corp. Set for Key Investor Conference Engagement
- Moving iMage Technologies Reflects on Fiscal Year 2024 Outcomes
- Celebrating Biotech Innovation: 2024 Endpoints 11 Winners Revealed
- Generate Capital Welcomes New Leaders to Drive Growth and Impact
Recent Articles
- Maddie's Fund Celebrates 30 Years of Transformative Impact
- Summer 2024: Unveiling Emerging Travel Trends
- Panasonic Connect Launches New Let’s note™ FV4 Laptop
- Essential Safety Guidelines Ahead of Hurricane Threats
- Hallmark's Strategic Moves in Healthcare Workforce Management
- BestEx Research Welcomes Stuart Baden Powell as APAC Leader
- Cardurion Pharmaceuticals Welcomes Ron Renaud to Leadership Team
- Gannett Launches Debt Exchange Offer to Enhance Financial Flexibility
- 858 Therapeutics Secures $50M in Series B Round for Innovations
- Bot Auto Secures $20M in Funding for Autonomous Truck Development
- CarMax Reports Lower Profits Despite Increased Vehicle Sales
- AbbVie's Late-Stage Trial Success for Parkinson's Treatment
- TotalEnergies Celebrates Milestone in CO2 Storage Technology
- Is Meta's Orion a Real Challenge for Apple's Future Vision?
- Crusoe Energy Joins Forces with VAST Data for Cloud Innovation
- Orchestra BioMed CEO Boosts Stake with Significant Share Acquisitions
- Spectrum Center Enhances Fan Safety with Evolv Technology
- BlackSky Gains US Navy Research Contract for Next-Gen Satellites
- GRI Bio Advances Research in Australia for IPF Treatment
- Rubrik and Pure Storage Unite to Elevate Cyber Resilience Efforts
- Expansion of Clean Fuel Initiatives by OPAL Fuels Inc.
- Xponential Fitness Partners with ACS for Breast Cancer Month
- Taysha Gene Therapies Unveils TSHA-102 Presentation Details
- Catawba Research Celebrates a Decade of Clinical Excellence
- Exploring Praxis Precision Medicines' Efficacy in Essential Tremor
- National Payroll Institute's Urgent Call for Financial Wellness
- AtoB Collaborates with Sunoco to Enhance Fuel Savings for Fleets
- CervoMed Announces Significant Research Findings for DLB
- IES Holdings Welcomes New Board Member John Louis Fouts
- Parents Fear Financial Dependence of Kids Beyond Adulthood
- Integer Holdings Corporation Announces Q3 Earnings Call Details
- Forging New Frontiers: Celebrating 50 Years of Creative Growth
- Growing Demand in Pharmaceutical Excipients Market by 2031
- Monte Carlo Welcomes Tim Miller as Chief Revenue Officer
- Leadership Transition at Pan American Energy Corp Site
- Upcoming Investor Conferences for electroCore: What to Expect
- Vertex Energy's Bankruptcy: A Journey Through Restructuring Plans
- o9 Partners with Li Auto to Transform EV Planning Strategy
- Bishop Street Underwriters Partners with Verve Services for Growth
- NICE Actimize Celebrates 2024 Innovation Award in Risk Management
- Trump's Legal Battles: Navigating Financial Liabilities Amidst Wealth Fluctuations
- Siemens Energy Leverages InfluxDB for Enhanced Operations
- Pacira BioSciences Presents Promising Data on PCRX-201 Treatment
- NaaS Technology Inc. Expands Horizon with IM Motors Partnership
- Razor Market Growth Projection to Reach Over $18 Billion by 2032
- 1&1 Versatel Enhances Nationwide Fiber Optic Network with Adtran
- Gaxos Labs Empowers Game Developers with AI Innovations
- Insights from Hilltop Securities Survey on Public Entities
- Vivani Medical's Obesity Implant Set for Clinical Trials in Australia
- Marco Di Giacomo Enhances Remote's Global Marketing Strategy